4863-70-1

Basic information

• Product Name: 4-(4-chlorophenyl)-3-phenylbutan-2-one
• Synonyms: 4-(4-chlorophenyl)-3-phenylbutan-2-one;4-(4-chlorophenyl)-3-phenyl-2-Butanone
• CAS NO: 4863-70-1
• Molecular Formula: C₁₆H₁₅ClO
• Molecular Weight: 258.7427
• Mol File: 4863-70-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 339.8°Cat760mmHg
• Flash Point: 207.6°C
• Appearance: /
• Density: 1.145g/cm³
• Vapor Pressure: 8.99E-05mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 4-(4-chlorophenyl)-3-phenylbutan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-chlorophenyl)-3-phenylbutan-2-one(4863-70-1)
• EPA Substance Registry System: 4-(4-chlorophenyl)-3-phenylbutan-2-one(4863-70-1)

Safety Data

• Hazardous Substances Data: 4863-70-1(Hazardous Substances Data)

Usage

Description

4-(4-chlorophenyl)-3-phenylbutan-2-one, commonly referred to as 4-CPP, is a chemical compound characterized by the molecular formula C16H15ClO. It presents as a yellowish crystalline solid with a slightly sweet odor. This ketone compound features a chlorophenyl and phenyl group attached to its carbon chain, endowing it with a range of biological activities. Recognized for its value as an intermediate in the development of therapeutic agents, 4-CPP is also known to exhibit moderate toxicity, necessitating careful handling with appropriate safety measures. It plays a significant role in the realm of organic synthesis and pharmaceutical research.

Uses

Used in Pharmaceutical Synthesis:
4-CPP is utilized as a key intermediate in the synthesis of various pharmaceuticals due to its unique chemical structure and biological activities. Its presence in the synthesis process aids in the development of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-CPP serves as a valuable building block for the creation of other organic compounds. Its versatility in forming different chemical entities makes it instrumental in advancing chemical research and development.
Used in Research and Development:
4-CPP is employed as a research compound to explore its biological activities and potential applications in medicine. Its use in research facilitates a better understanding of its properties and helps in the discovery of new drugs and treatments.
Used in Safety and Toxicity Studies:
Given its moderate toxicity, 4-CPP is also used in studies aimed at understanding its safety profile and developing appropriate handling and disposal protocols to minimize risks in laboratory and industrial settings.

InChI:InChI=1/C16H15ClO/c1-12(18)16(14-5-3-2-4-6-14)11-13-7-9-15(17)10-8-13/h2-10,16H,11H2,1H3

Upstream product

• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 103-79-7 1-phenyl-acetone 
• 37509-49-2 4-(4-chlorophenyl)-3-phenyl-2-oximino-but-3-ene 
• 698-87-3 3-phenyl-2-propanol 
• 622-95-7 4-chlorobenzyl bromide 
• 6318-76-9 (E)-4-(p-chlorophenyl)-3-phenyl-3-buten-2-one 
• 101-41-7 benzeneacetic acid methyl ester 
• 92907-23-8 3-(4-chlorophenyl)-2-phenylpropanoic acid methyl ester 
• 2901-30-6 (±)-3-(4-chlorophenyl)-2-phenylpropanoic acid 
• 1017454-48-6 3-(4-chlorophenyl)-2-phenylpropanoyl chloride 
• 605679-89-8 N-methoxy-N-methyl-3-(4-chlorophenyl)-2-phenylpropanamide 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 110149-45-6 4-(4-chloro-benzyl)-5-oxo-4-phenyl-hexanenitrile 
• 4814-11-3 N-[3-(4-chlorophenyl)-2-phenyl-1-methylpropyl]-amine hydrochloride 
• 605679-93-4 2-(N-tert-butoxycarbonylamino)-4-(4-chlorophenyl)-3-phenylbutane 
• 605679-91-2 4-(4-chlorophenyl)-2-methanesulfonyloxy-3-phenylbutane 
• 605679-92-3 2-azido-4-(4-chlorophenyl)-3-phenylbutane 
• 54636-47-4 8-(4-Chloro-benzyl)-9-oxo-8-phenyl-decanoic acid 
• 605679-90-1 4-(4-chlorophenyl)-3-phenyl-2-butanol 
• 54636-48-5 8-(4-Chloro-benzyl)-9-oxo-8-phenyl-decanoic acid ethyl ester 

Relevant articles and documents

Synthesis of β-Amino Diaryldienones Using the Mannich Reaction

The Mannich reaction has been used for decades to prepare many pharmaceutically important molecules. Here, using a "double-Mannich-β-elimination" synthetic sequence, we report the synthesis and the characterization details of a novel class of β-amino diaryldienones with prominent antiprostate cancer activity. Through these studies, we correct an erroneous structure in the current literature, present a discussion of the stereochemical outcome of a new reaction, and probe the mechanism(s) of byproduct formation through isotopic studies.

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.

ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.